RIQAS Pre-eclampsia EQA Programme – Cycle Starts July 2025
Ensure Accuracy in Pre-eclampsia Testing with our New EQA Programme starting July 2025. The programme is designed to support laboratories in ensuring the reliability of biomarker testing for pre-eclampsia, helping to improve patient care and outcomes.
Join the many laboratories worldwide committed to excellence in diagnostics!
- Human based high quality serum samples to challenge your laboratory’s performance.
- Lyophilised samples for improved stability.
- Comprehensive yet easy to interpret results.
- Report turnaround time of less than 72-hours.
- Monthly reporting to monitor and maintain testing accuracy.
- As the largest EQA scheme globally peer group numbers are maximised.
- Cycle Starts – July 2025.
Not accredited to ISO 17043
Frequency
Monthly
Samples
12 x 1 ml
Material
Human Based
| Cat No | Kit Size | Frequency | Parameters | |
|---|---|---|---|---|
| RQ9207 | 12 x 1ml | Monthly | 4 parameter | |
The Pre-eclampsia programme is designed to monitor a laboratory’s ability to correctly determine the outcome of the following tests that are useful for screening, diagnosing, predicting and monitoring placenta-related disorders.
Parameters
- PAPP-A (Pregnancy associated plasma protein-A)
- PlGF (Placental Growth Factor)
- sFlt-1 (soluble fms-like tyrosine kinase-1)
- sFlt-1/PlGF ratio
Related Products
What is Pre-eclampsia and why is testing important?
Pre-eclampsia (PE) is a heterogenous, multisystem disorder specific to pregnancy. It is defined as the new onset of hypertension accompanied by one or more of the following, after 20 weeks gestation:
- Proteinuria
- Maternal organ dysfunction (e.g., Acute kidney injury, liver involvement, neurological complications, haematological complications)
- Uteroplacental dysfunction
PE affects around 2-7% of pregnancies and accounts for approximately 500,000 foetal/neonatal and 70,000 maternal deaths every year exhibiting a clear burden on healthcare services in both developed and developing countries.
Accurate diagnosis of PE is likely to decrease unnecessary hospitalisations, overdiagnosis and overtreatment of patients.